Abstract |
The bispecific monoclonal antibody (biMAb) OC/TR combines the anti- ovarian-cancer reactivity of the MOv18 monoclonal antibody (MAb) with the reactivity of an anti-CD3 MAb. Pre-clinical studies have indicated that this biMAb is able to redirect the cytolytic activity of T cells towards tumour cells, resulting in efficient tumour-cell lysis. To assess the clinical potential of systemic biMAb-based cancer therapy we initiated a study in ovarian-cancer patients. Five patients suspected of ovarian cancer received 123I- OC/TR F(ab')2 i.v. Unexpectedly, the first patient developed side effects (grade III-IV toxicity) starting 30 min after infusion (p.i.) of 1 mg of OC/TR F(ab')2. After approval of the Ethical Committee, the study was continued at lower dose levels (0.1 mg; 0.2 mg). However, at the 0.2-mg dose level similar side effects were observed. FACS analysis indicated that all peripheral T cells were coated with biMAb immediately following the infusion. The cytokines tumour necrosis factor- alpha, interferon-gamma and interleukin-2 showed maximum serum concentrations 2 h p.i. Tumour uptake ranged from 0.8 to 1.9% ID/kg, resulting in tumour/background ratios of 3 to 8. Our results suggest that at higher antibody dose levels OC/TR F(ab')2 causes T-cell activation with acute release of cytokines. Only low doses of biMAb can be administered safely. Despite the interaction with T cells, OC/TR F(ab')2 preferentially localizes in tumours following i.v. administration, thus offering therapeutic perspectives.
|
Authors | J G Tibben, O C Boerman, L F Massuger, C P Schijf, R A Claessens, F H Corstens |
Journal | International journal of cancer
(Int J Cancer)
Vol. 66
Issue 4
Pg. 477-83
(May 16 1996)
ISSN: 0020-7136 [Print] United States |
PMID | 8635863
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibodies, Bispecific
- Antibodies, Monoclonal
- CD3 Complex
- Carrier Proteins
- Folate Receptors, GPI-Anchored
- Immunoglobulin Fab Fragments
- Receptors, Cell Surface
- Tumor Necrosis Factor-alpha
|
Topics |
- Adenocarcinoma
(diagnostic imaging, therapy)
- Antibodies, Bispecific
(administration & dosage, adverse effects, metabolism, pharmacokinetics)
- Antibodies, Monoclonal
(administration & dosage, adverse effects, metabolism, pharmacokinetics)
- CD3 Complex
(immunology)
- Carrier Proteins
(immunology)
- Cystadenoma
(therapy)
- Dose-Response Relationship, Immunologic
- Female
- Folate Receptors, GPI-Anchored
- Humans
- Immunoglobulin Fab Fragments
(metabolism)
- Immunotherapy
- Infusions, Intravenous
- Ovarian Neoplasms
(diagnostic imaging, therapy)
- Radionuclide Imaging
- Receptors, Cell Surface
- Tissue Distribution
- Tumor Necrosis Factor-alpha
(metabolism)
|